Twitter Beğeni Hilesi

Proof of concept is proven. R&D Spotlight released early September (despite being recorded in H1) promising the pipeline ‘very soon’ means there is - quite clearly - a choreography to #AVCT’s news flow this time around. One can’t progress a pipeline without funding…

Here’s the INDEPENDENT investigator view. Also note there were zero cardiac events over a 38 month period. Unheard of for naked doxorubicin. #AVCT

Even by #AVCT’s historic standards today has been madness. The trial is a safety trial. That safety profile has proven to be quite remarkable. See below. AVCT is dosing patients who should never have responded. Indeed, those patients responding failed all other options before

Looking for the positives in this debacle. Every hot take is laughable. Thus providing a platform to explain why what #AVCT has achieved over 38 months is so impressive. AVA6000 was only intended to prove safety in P1a. Not only is it also efficacious but it proves preCISION.

Trinity note out. 188p price target. #AVCT trinitydelta.org/wp-content/upl…

Phase Ia data at #ESMO2024 provide further PoC for #AVA6000 & targeted release of dox; PK data suggest wider applicability of pre|CISION platform in solid tumours w lower FAP expression. Avacta's Q4 pipeline review/science day to provide more info. #AVCT trinitydelta.org/companies/avac…

There were many colorectal cancer patients in the phase 1 trial “Im not convinced colorectal cancer responds to doxorubicin, even if you give a lot of it” (medical oncologist, professor Twelves) Yet, Paul Cuddon is questioning why AVA6000 isn’t shrinking these tumours #AVCT

Paul Cuddon has zero idea on how to interpret trial data. Better to listen to Dr Tap Paul Cuddon is clearly unaware over 80% of STS patients will not have meaningful responses to Dox He is also unaware that 6K allows patients to stay on drug for much longer. #AVCT

Paul Cuddon has no idea that the toxicity of Doxorubicin limits its use. He has no idea that AVA6000 dramatically improves the safety profile of Doxorubicin meaning patients can say on drug for longer. This improves the most important outcomes: PFS & OS #AVCT

Paul Cuddon has no idea that 35% of patients will experience serious adverse events when being treated with Dox. Cuddon has no idea that if these patients had taken AVA6000 instead the vast majority (potentially all) would not have experienced an adverse event #AVCT

Cuddon is also unaware that due to the remarkable safety profile of AVA6000, it is now likely that Doxorubicin will be available to those over the age of 65 “The benefit of Doxorubicin is being on drug, not stopping drug” (Dr Tap) #AVCT

This thread is an absolute decimation of the Cuddon note via clips of Dr Tap. Brilliant. #AVCT

Whilst it took the shareholder base a while to find a coherent voice, the Cuddon lines have been systemically debunked with impressive clarity/depth. A sub section of the #AVCT shareholder base is so well informed. Now time for the rest of the market to catch up!

Here&There Tim Kempster Kevin Taylor AVA6k will be going head 2 head with Doxorubicin as a 1st line therapy in STS. This is what it has to beat: ORR 18% PFS 6months OS 19 months If you think the trial results to date don’t suggest that AVA6000 has every chance in bettering these then you are a troll #AVCT

The rug pulls for #AVCT, which was apparently caused by Deutsche Bank Zaks Traders Cafe querying the company Fundamental data and have not known. With 35 years of listing to the big city investment banks, l have not known them to be that helpful, or correct. They tend to be an